TB DRUG MONOGRAPHS
  • Home
  • Baseline & Ongoing Monitoring Tests
  • Drug Monographs
    • Amikacin
    • Bedaquiline
    • Capreomycin
    • Clarithromycin
    • Clofazimine
    • Co-Amoxiclav
    • Cycloserine
    • Delamanid
    • Ethambutol
    • Imipenem/Cilastatin
    • Isoniazid
    • Levofloxacin
    • Linezolid
    • Meropenem
    • Moxifloxacin
    • Ofloxacin
    • P-aminosalicylic acid
    • Pretomanid
    • Prothionamide
    • Pyrazinamide
    • Rifabutin
    • Rifampicin
    • Rifapentine
    • Streptomycin
    • Terizidone
    • Thioacetazone
  • For patients
  • Updates
  • Publications
  • References
  • About Us
  • Contact

CO-AMOXICLAV

DOSAGE
Adults: 250mg/125mg of amoxicillin/clavulanic acid two to three times a day, given 30 minutes prior to each carbapenem dose.
Children: Limited data. The Sentinel Project advise 40mg/kg of amoxicillin twice a day, given 30 minutes prior to each carbapenem dose. (Maximum of 500mg per day of clavulanic acid).
PREPARATIONS
Oral:      250/125mg (375mg), 500/125mg (625mg) tablets.
               125/31mg, 250/62mg suspension.
Parenteral: 500/100mg, 1000/200mg Powder for solution for injection or infusion.
 
DRUG LEVEL MONITORING
  • Drug levels need not be routinely measured.
 
ADVERSE EFFECTS
COMMON:
Dermatological: Rash & urticaria (3%).
Gastrointestinal: Nausea & vomiting (1-5%), diarrhoea (9%).
Infective: Candidiasis, particularly oral and vaginal (1%).
SERIOUS:
Dermatological: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis.
Hepatic: Hepatitis, cholestatic jaundice.
Immunological: Anaphylaxis.
 
ADVERSE EFFECTS: MONITORING
Routine tests as per generic MDR-TB treatment monitoring guidelines.
 
INTERACTONS
No common serious drug interactions usually expected.
Anticoagulants: Case reports of increased INR in patients taking acenocoumarol or warfarin and prescribed a course of amoxicillin. Monitor INR.
 
This information is not inclusive of all drug interactions. Please discuss with a pharmacist.
 
CONTRA-INDICATIONS & CAUTIONS
Contraindications:
Hypersensitivity: To penicillins.
Liver Disease: Previous history of jaundice/hepatic impairment due to co-amoxiclav.
 
Cautions:
Pregnancy & Breast-feeding
Renal Disease: Use with caution. Reduce dose in severe renal impairment.
Liver Disease: Use with caution. Monitor liver function. Cholestatic jaundice may occur during or shortly after the use of co-amoxiclav. Risk is higher in patients aged >65 years and in men.
 
LABORATORY INFORMATION
Please find up to date information at www.assayfinder.com regarding individual providers of drug level monitoring tests. Click on the provider to discover contact details.  Turnaround time varies depending on the test and whether it is run locally or sent to an external lab.  By contacting laboratories in advance, turnaround time can significantly be reduced.

 

The information we have provided here is not exhaustive and is aimed as a practical tool for aid in the management of patients with MDR-TB.  A list of references is included in a separate document however the majority of these recommendations are based on expert consensus.   Feedback is welcomed.  This is a drug monitoring guideline, for treatment guidance please refer to the WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment https://www.who.int/publications/i/item/9789240007048  and the BTS MDR-TB Clinical Advisory Service www.brit-thoracic.org.uk/quality-improvement/lung-disease-registries/bts-mdr-tb-clinical-advice-service/